Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy ProgramSeeking Alpha • 11/30/23
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?The Motley Fool • 11/30/23
Arecor extends its relationship with Lilly as it inks another technology dealProactive Investors • 11/29/23
Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript)Seeking Alpha • 11/29/23
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock DivesInvestors Business Daily • 11/28/23
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San DiegoPRNewsWire • 11/28/23
Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis findsReuters • 11/27/23
Eli Lilly's Mounjaro three times more effective than Ozempic for weight loss, real-world study findsMarket Watch • 11/27/23
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of tradeMarket Watch • 11/22/23
Eli Lilly Stock Nears Another Record As Drugmaker Enters The Weight-Loss ArenaInvestors Business Daily • 11/20/23